ME
Medicamen Biotech Ltd (MEDICAMEQ)
₹286.00
Mkt cap
₹405 Cr
P/E ratio
35.00
P/B
1.38
Div yield
0.35%
ROE
3.95%
ROCE
5.82%
EPS (TTM)
₹8.17
Book value
₹208
52W range
210–454
Sector
Healthcare
Price history
Previous close
Incorporated in 1993, Medicamen Biotech Ltd is a research-led pharmaceutical company involved in developing, manufacturing, and marketing generic finished dosage formulations, and Oncology Formulations [1]
NSE MEDICAMEQBSE 531146
Health check
Cautious
ValuationFair
ProfitabilityWeak
GrowthModerate
52-week range
₹286
₹210₹454
Current
₹286.00
Prev close
—
Day
—
Financials
Revenue, profit & margin
P/E ratio
35.0×
MEDICAMEQ is 8% above the sector median of 32.5×
MEDICAMEQ35.0×
Sector median32.5×
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 43.54 | 46.50 | 47.32 | 43.05 | 44.74 | 45.14 | 29.61 | 43.04 | 47.17 | 46.91 | 60.65 | 47.90 | 54.83 | |
| YoY Sales growth | +29.85% | +30.69% | +22.37% | +2.65% | +2.76% | -2.92% | -37.43% | -0.02% | +5.43% | +3.92% | +104.83% | +11.29% | +16.24% | |
| Expenses | 38.89 | 41.60 | 41.57 | 39.60 | 39.43 | 38.43 | 31.22 | 38.43 | 42.01 | 42.53 | 55.22 | 43.57 | 46.15 | |
| Operating Profit | 4.65 | 4.90 | 5.75 | 3.45 | 5.31 | 6.71 | -1.61 | 4.61 | 5.16 | 4.38 | 5.43 | 4.33 | 8.68 | |
| OPM % | 10.68% | 10.54% | 12.15% | 8.01% | 11.87% | 14.86% | -5.44% | 10.71% | 10.94% | 9.34% | 8.95% | 9.04% | 15.83% | |
| Other Income | 0.55 | 0.83 | 0.57 | 0.59 | 0.29 | 0.14 | 5.23 | 0.47 | 0.37 | 0.53 | 1.74 | 0.86 | 0.00 | |
| Interest | 0.91 | 0.65 | 1.89 | 0.71 | 1.04 | 0.76 | 0.65 | 1.15 | 0.99 | 0.97 | 0.38 | 0.83 | 1.69 | |
| Depreciation | 1.82 | 1.80 | 1.77 | 1.77 | 2.61 | 2.21 | 0.48 | 1.80 | 1.86 | 1.83 | 1.73 | 1.79 | 1.87 | |
| Profit before tax | 2.47 | 3.28 | 2.66 | 1.56 | 1.95 | 3.88 | 2.49 | 2.13 | 2.68 | 2.11 | 5.06 | 2.57 | 5.12 | |
| Tax % | 39.68% | 38.11% | 22.93% | 48.72% | 53.85% | 24.74% | 25.30% | 24.88% | 21.27% | 22.27% | 12.06% | 28.40% | 19.53% | |
| Net Profit | 1.47 | 2.03 | 2.04 | 0.80 | 0.91 | 2.92 | 1.87 | 1.60 | 2.12 | 1.64 | 4.45 | 1.85 | 4.12 | |
| EPS in Rs | 1.19 | 1.90 | 1.68 | 1.06 | 1.15 | 2.73 | 1.90 | 1.59 | 1.97 | 1.61 | 2.85 | 1.56 | 2.51 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
as of Oct 202642.57%Promoter
Promoters42.57%2.11
FIIs4.35%0.14
DIIs0.00%
Public53.01%1.99
Government0.05%
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,884.90 | 36.70 | 4,51,538 | 0.85% | 1,995 | −10.53% | 16,199 | +11.88% | 20.53% |
| Divi's Lab. | ₹11,180.50 | 86.86 | 2,96,807 | 0.27% | 1,127 | +63.57% | 3,676 | +35.40% | 21.97% |
| Torrent Pharma. | ₹4,689.50 | 82.07 | 1,78,180 | 0.81% | 534 | −10.03% | 4,979 | +50.79% | 15.19% |
| Laurus Labs | ₹2,294.60 | 92.69 | 1,24,195 | 0.09% | 436 | +126.43% | 2,206 | +33.44% | 17.76% |
| Zydus Lifesci. | ₹1,200.00 | 26.48 | 1,19,990 | 0.08% | 928 | −27.96% | 7,910 | +29.17% | 21.14% |
| Dr Reddy's Labs | ₹1,390.20 | 41.56 | 1,16,360 | 0.58% | 913 | −31.35% | 8,698 | −1.48% | 13.04% |
| Cipla | ₹1,415.00 | 36.88 | 1,14,518 | 0.92% | 852 | −35.05% | 7,404 | −2.44% | 15.49% |
| Medicamen Biotec | ₹285.90 | 35.01 | 405 | 0.35% | 4 | +27.72% | 55 | +16.24% | 5.82% |
| Median: 160 Co. | ₹432.20 | 32.47 | 1,987 | 0.08% | 13 | +33.73% | 179 | +21.23% | 14.94% |
Filings
Annual reports15
Concall transcripts5
Credit ratings6
Announcements5
Announcement under Regulation 30 (LODR)-Newspaper Publication 16 NovFinancial Results - Quarter And Half Year Ended On September 30, 2026 13 NovBoard Meeting Intimation for Considering And Approving The Unaudited Financial Results (Standalone And Consolidated) Of The Company For The Quarter And Half Year Ended On September 30, 2026. 6 Nov - Board meets on November 13, 2026 to approve Q2 and half-year unaudited results; trading window closedOctober 1.Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 26 Oct - Certificate under Regulation 74 (5) of SEBI (DP) Regulation 2018- September 30, 2026Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 26 Oct






